Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$34.53
neg -0.06
-0.17%
Today's Range: 34.41 - 34.66 | PFE Avg Daily Volume: 28,670,400
Last Update: 02/27/15 - 12:02 PM EST
Volume: 7,177,475
YTD Performance: 11.04%
Open: $34.41
Previous Close: $34.59
52 Week Range: $27.51 - $34.97
Oustanding Shares: 6,300,657,237
Market Cap: 218,380,779,834
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 7
Moderate Buy 1 1 1 1
Hold 3 3 4 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.85 1.92 2.00 2.00
Latest Dividend: 0.28
Latest Dividend Yield: 3.23%
Dividend Ex-Date: 02/04/15
Price Earnings Ratio: 21.40
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
21.40 24.40 26.73
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.22% 8.13% 63.31%
GROWTH 12 Mo 3 Yr CAGR
Revenue -12.50 -0.26 -0.10
Net Income -58.50 0.04 0.01
EPS -55.50 0.13 0.04
Earnings for PFE:
EBITDA 17.54B
Revenue 49.61B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.48 $0.53 $2.07 $2.23
Number of Analysts 5 5 8 8
High Estimate $0.49 $0.55 $2.09 $2.30
Low Estimate $0.45 $0.53 $2.04 $2.13
Prior Year $0.57 $0.58 $2.26 $2.07
Growth Rate (Year over Year) -16.49% -7.93% -8.41% 7.49%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Feb 23, 2015 | 11:59 AM EST

It is no pipedream that the stock could trade to $240.

By

Gary Morrow

 | Feb 18, 2015 | 3:13 PM EST

A continued fade back down offers a buying opportunity.

bullishPfizer upgraded at BMO

Feb 9, 2015 | 7:10 AM EST

PFE was upgraded from Market Perform, to Outperform, BMO Capital said. $36 price target. Hospira deal could mark an inflection point in valuation. 

By

Jim Cramer

 | Feb 6, 2015 | 7:40 AM EST

The logic of owning the pure play is attractive.

bullishPfizer estimates, target increased at BMO

Feb 4, 2015 | 8:08 AM EST

PFE estimates were raised through 2016, BMO Capital said. Company received accelerated approval for breast cancer treatment. Market Perform rating and new $33 price target. 

By

Bret Jensen

 | Jan 31, 2015 | 12:00 PM EST

The financial version will affect global equity markets.

By

Jim Cramer

 | Jan 29, 2015 | 1:52 PM EST

Such activity means a rush to the exits.

By

Bret Jensen

 | Jan 29, 2015 | 9:46 AM EST

I am adding allocation to healthcare.

By

Chris Versace and Lenore Hawkins

 | Jan 28, 2015 | 6:00 PM EST

Corner of Wall & Main on Apple, the Fed and a stronger dollar.

By

Ed Ponsi

 | Jan 28, 2015 | 11:00 AM EST

These 2 consumer-products giants stand to benefit from a strong greenback.

The CCMP Index has generated long-term, overbought conditions in 2000, 2007 and since 2013...

AAPL Watch to contain technology that will eventually unlock your car/replace your keys

VIX is stuck with very steep skew keeping the index elevated. Until the skew in SPX start...
Ingram Micro (IM) is cheap today after reporting good earnings, although they were hurt by...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.